drugset / Trial / NCT01719003

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003

Phase 3 Completed 1413 enrolled Boehringer Ingelheim Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.

Timeline

Start
2012-10
Primary completion
2014-11
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 5 mg Oral
Subject Empagliflozin Small molecule 10 mg Oral
Subject Empagliflozin Small molecule 12.5 mg Oral
Subject Empagliflozin Small molecule 25 mg Oral
Subject Metformin Small molecule 500 mg Oral
Subject Metformin Small molecule 1000 mg Oral